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Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma and the clinical management of patients with
unresectable, metastatic disease is still challenging. ASPS expresses an array of potentially therapeutically targetable,
angiogenesis-related molecules and, importantly, it has a distinctive angiogenic phenotype marked by a peculiar
tumor-associated vasculature. Several studies, conducted in transgenic mouse models and in a large variety of
human tumors of different histotype, clearly proved the substantial contribution of tumor-infiltrating myeloid cells,
such as myeloid derived suppressor cells, monocytes and macrophages, in the formation and maintenance of
abnormal blood vessels in tumors. By immunohistochemistry we thus explored the presence and the distribution of
cells expressing myeloid markers in the inflammatory infiltrate of surgical treated metastatic ASPS. Indeed, we found
that myeloid cells expressing CD14 and CD163 markers constitute the prominent cells in the inflammatory infiltrate
of ASPS. These macrophage-like cells form a network surrounding the endothelial cells, or, interspersed in the
tumor nest, they keep deep contact with tumor cells. In this commentary, we discussed our findings in relation to
the recently published paper by Kummar and colleagues reporting the clinical and molecular results of a phase II
clinical trial in patients with unresectable, metastatic ASPS treated with the anti-angiogenic drug cediranib,
targeting the VEGFR-1,-2,-3 tyrosine kinases.
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We read with great interest the paper by Kummar et al.
on cediranib in metastatic alveolar soft part sarcoma
(ASPS) [1]. The study evaluated the antitumor activity of
cediranib in 43 patients. The disease control rate (partial
response plus stable disease) of patients who completed
the therapy course was 84%. Tumor biopsies prior and
after one week of cediranib were obtained from a subset of
patients. Thus, the authors investigated for the first time
the gene expression changes in ASPS after anti-angiogenic
treatment, giving a comprehensive overview of the micro-
array/qRT-PCR profiles of significantly modulated genes in
7 validated cases. Included in this list are genes playing a
direct role in the cancer driven neo-angiogenesis. Tumor
lesions from patients treated with cediranib displayed a
selective down-regulation of angiopoietin 2 (ANGPT2) and* Correspondence: Licia.Rivoltini@istitutotumori.mi.it
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reproduction in any medium, provided the orthe up-regulation of its receptor TIE2. This opposite gene
modulation may favor the angiopoietin 1 (ANGPT1)-TIE2
interaction and, together with the down-modulation of
VEGFR1 (FLT1) and VEGFR2 (KDR), drive a physiological
normalization of the vasculature at tumor site [2]. This
hypothesis is also supported by the findings that genes
encoding for proteins expressed by endothelial precursor
cells or by the tumor-associated neo-vasculature such as
Folate receptor 1 (FOLH1, known also as PMSA), CXCR7
and ESM1, [3-6] were also down-modulated. Gene profiling
also revealed that in cediranib treated ASPS, CCL2 mRNA
was associated to the presence of high level of CD163
gene expression. This coordinated gene up-regulation may
suggest the selective recruitment of inflammatory mono-
cytes that differentiate into fully mature macrophages at
tumor site. However, CD163 is a marker associated to
M2-like macrophages, endowed with pro-tumor and
pro-angiogenic functions. Furthermore, the up-regulated
expression of TIE2 in post treated samples can also be
indicative of an increased accumulation of TIE2+ cells,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in tumor-mediated neo-angiogenesis [7]. Thus, it is difficult
to reconcile this complex scenario with the observation that
the majority of the examined ASPS biopsies indeed derived
from patients displaying a clinical response to treatment.
The precise knowledge of the type, functional polarization
and localization of immune tumor infiltrating cells in ASPS
will possibly be of help in interpreting these data. While the
Authors studied post-treatment changes on extractive tis-
sues, we examined pre-treatment morphological and bio-
chemical profiles of metastatic ASPS. We have investigated
the pre-treatment immunophenotypic and biochemical
profiles of 7 out of 15 patients treated with sunitinib since
2007 [8,9]. These 7 patients received surgery in our institute
before treatment with sunitinib and their tumor tissues
were available for immunohistochemistry (IHC) analysis.
The other 8 patients underwent surgery elsewhere and
material for the analyses was not at disposal. Moreover,
ethical issues restrained the analysis of post-treated ASPS
since there was no clinical indication for surgery after
sunitinib. In a semi-quantitative scoring system, all the 7
samples displayed similar distribution and density for all
the studied markers. An example, explicative for all the
examined ASPS, is depicted in Figure 1. As showed in
Figure 1, pre-treatment ASPS consisted of a sizeable
population of CD163+ cells found in two distinct localiza-





Figure 1 Macrophages are key components of the inflammatory micr
Immunohistochemical analysis of CD163+ cells infiltrating an untreated AS
cells are found in two distinct localizations: they are interspersed within ne
region (arrows). (B) Confocal microscopy imaging of CD163+ cells (green)
CD14 staining closely resembles that of CD163 (D) and double staining co
macrophages (red). (E) A similar distribution of immunoreactivity is observecells but, most importantly, they were also clearly detectable
in the perivascular region where CD163+ cells (Figure 1
panels A and B, lower and higher magnification, respect-
ively) were aligned to VEGFR2+ cells of endothelial nature
(Figure 1, panel C: CD163 -NCL-CD163, Leica-Novocastra-
green; VEGFR2 -55B11, Cell Signaling Technology- red).
The CD163+ cells were also CD14+ (Figure 1, panel D)
and therefore identifiable as tumor associated macrophages,
and consequently aligned to CD31+ cells (panel E: CD14 -
MS-1080-S1, Thermo Scientific- red; CD31 -JC70A, Dako-
green). Of note, a similar distribution of immunoreactivity
was observed for CSFR-1 (panel F: C20, sc-692, Santa Cruz
Biotechnology). In addition, our previous investigation
showed that CSFR-1 not only was expressed but also acti-
vated [8]. The CSF-1/CSF-1R signaling axis is the major
regulator of survival, proliferation and functional differen-
tiation of macrophages. All together, our observations
established the presence of M2-like, CD163+ CD14+ mac-
rophages in the tumor microenvironment of naive ASPS.
These myeloid cells are active inflammatory components
that may promote VEGF-mediated vasculogenesis and,
although not physically part of the vasculature, they are
thought to provide trophic support to the characteristic
ASPS vascular network. The pre-treatment immunophe-
notypic ASPS signature we observed strongly suggest that
myeloid immune component of the ASPS microenviron-




oenvironment in metastatic alveolar soft part sarcoma.
PS lesion (A-B). As evidenced by the higher magnification image these
st tumor cells (circle) and they are also detectable in the perivascular
shows that they are aligned to endothelial VEGFR2+ cells (red) (C).
nfirms that CD31+ endothelial cells (green) are lined by CD14+
d for CSFR-1 (F).
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VEGFR drugs, such as cediranib. However, Kummar’s
data indicated that the CCL2 and CD163 genes, known
markers of inflammatory myeloid cell infiltration and
associated with M2-like pro-tumor macrophages, were
boosted in those ASPS of patients treated with cediranib
with evidence of response. The absence of drug-induced
down-regulation in the myeloid inflammatory components
raises questions concerning its possible association with
the profile of the tumor, with response or resistance to
treatment. At first, we can argue that cediranib treatment
may induce a functional shift of the infiltrating myeloid
cells instead of modulating their frequency at tumor site
(that would have ended up with a diminished expression of
genes encoding for markers of myeloid cells). Indeed, the
active role of VEGF/VEGFR signaling in the functional
generation of myeloid cells with strong pro-angiogenic
and immunosuppressive functions is amply documented
both in animal models and in humans [10]. Thus, by
blocking this pathway, cediranib might affect the type or
the functional status of the inflammatory cells, eventually
contributing to the transformation of the immunosup-
pressive, pro-angiogenic microenvironment into a more
immunostimulatory, anti-tumor milieu [11]. In support of
this interpretation, cediranib up-regulated the inflamma-
tory pathway genes controlled by the nuclear factor-kB, as
highlighted by the authors themselves. This strong and
coordinated boost of inflammation-related genes might
transform the chronic, pro-tumorigenic inflammation at
the tumor site into an acute inflammation status that is
perceived by the immune system as ‘dangerous’ and is
generally correlated with an active, protective immune
response [12]. In addition, as recently reported in different
tumor settings [13], anti-angiogenic therapy induces a
vascular normalization that alleviates tumor local hypoxia,
thus removing one of the major factors responsible for
the generation of an immunosuppressive environment
[14]. As an alternative hypothesis, it cannot be excluded
that M2-like pro-angiogenic myeloid cells present at
tumor site, as shown by our immunophenotyping stud-
ies, might increase in number to counteract the massive,
antiangiogenic-mediated vascular pruning. Indeed, in
such a case, M2 polarized myeloid cells could be the
immune-related mediators of acquired resistance. To de-
cipher the role of this ‘inflammatory’ component in ASPS
treated with cediranib, and, more in general, for the anti-
angiogenic therapies of solid tumors, it will be crucial to
assess whether or not the localization and the functional
activation of the myeloid cells, resident or newly recruited,
in treated ASPS overlap with those found in pre-treated
tumors. This matter can only be dissected through a
thorough pre/post-treatment analysis of pair-matched
ASPS samples. Nonetheless, the gene expression changes
induced in ASPS after cediranib treatment and the presenceof a structured myeloid cell infiltration provide the rationale
for further studies to investigate the feasibility of ap-
proaches targeting myeloid cells in combination with
anti-angiogenic therapy. Drugs limiting the viability,
function and differentiation of cells of myeloid lineage
have been recently introduced in clinical setting. Among
them all-trans-retinoic acid (ATRA), with differentiation
potential, and synthetic triterpenoids, that reduce the
intracellular reactive oxygen species, molecules mediating
the suppressive function of MDSC and macrophages,
have been recently used in pilot clinical studies [15,16].
Furthermore, trabectedin has been recently shown to
limit the viability of monocytes and tumor-associated
macrophages in sarcomas [17], and bisphosphonates,
employed in the treatment of bone metastasis, may also
potentially target macrophages [18]. In conclusion, the
precise knowledge of the nature of tumor infiltrating
cells before and after a given drug treatment may pave
the way to new combined therapies aimed at overcoming
drug induced resistance.
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